{
    "clinical_study": {
        "@rank": "34987", 
        "acronym": "CSM/ON/2011", 
        "arm_group": {
            "arm_group_label": "Mesenchymal Stem Cell", 
            "arm_group_type": "Experimental", 
            "description": "Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.\nThey employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.\nPharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to analyze the safety and feasibility of direct administration\n      intrafemoral mesenchymal stem cells (MSCs) in vitro expanded autologous treatment of\n      patients with femoral osteonecrosis."
        }, 
        "brief_title": "PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells", 
        "condition": "Osteonecrosis of the Femoral Head", 
        "condition_browse": {
            "mesh_term": "Osteonecrosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 18 and 70 years\n\n          -  Clinical diagnosis and imaging (Rx and NMR) of idiopathic osteonecrosis of the\n             femoral head\n\n          -  Stadiums <IIIC ARCO ranking\n\n        Exclusion Criteria:\n\n          -  Those on investigator judgment not in a good position to tolerate the procedure.\n\n          -  Clinical criteria and anesthetics that contraindicate surgery (eg ASA IV-V)\n\n          -  Serious illness uncontrolled\n\n          -  Pregnant women\n\n          -  Patients with HIV infection +\n\n          -  Acute infection (in the previous 15 days) or chronic (other than HIV)\n\n          -  Previous treatments of osteonecrosis\n\n          -  Active or previous neoplastic disease (last 5 years) except for patients undergoing\n             allogeneic haematopoietic progenitors who are in complete remission after 2 years\n             after transplantation.\n\n          -  Lack of informed consent or revocation thereof."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "10", 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700920", 
            "org_study_id": "CSM/ON/2011"
        }, 
        "intervention": {
            "arm_group_label": "Mesenchymal Stem Cell", 
            "intervention_name": "bone marrow aspirate", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Osteonecrosis of the femoral head", 
            "Stem Cell", 
            "Mesenchymal Stem Cells", 
            "Femoral Head"
        ], 
        "lastchanged_date": "October 2, 2012", 
        "link": [
            {
                "description": "Spanish cell therapy network (TerCel)", 
                "url": "http://www.red-tercel.com"
            }, 
            {
                "description": "Salamanca University Foundation", 
                "url": "http://fundacion.usal.es"
            }, 
            {
                "description": "Spanish Health Institute Carlos III", 
                "url": "http://www.isciii.es"
            }
        ], 
        "location": {
            "contact": {
                "email": "juanfblanco@telefonica.net", 
                "last_name": "Juan F Blanco, Doctor", 
                "phone": "+34 923 291 100"
            }, 
            "facility": {
                "address": {
                    "city": "Salamanca", 
                    "country": "Spain", 
                    "state": "Castilla y Le\u00f3n", 
                    "zip": "37007"
                }, 
                "name": "University Hospital of Salamanca"
            }, 
            "investigator": [
                {
                    "last_name": "Ferm\u00edn M S\u00e1nchez-Guijo, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Juan F Blanco, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Ethics Committee", 
                "Spain: Ministry of Health", 
                "Spain: Spanish Agency of Medicines"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Red de Terapia Celular", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Haematology Service,University Hospital of Salamanca, M\u00aaConsuelo del Ca\u00f1izo Fern\u00e1ndez-Rold\u00e1n", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Spanish National Health System", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Red de Terapia Celular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}